Subscribe to RSS
DOI: 10.1055/a-1241-2407
Metformin-Therapie bei operativen Eingriffen und Gabe jodhaltiger Kontrastmittel
Metformin Therapy During Surgical Interventions and Iodinated Contrast Agent UseDas perioperative und das periinterventionelle Management von Metformin bei Verwendung von Kontrastmitteln zu Diagnosezwecken wird in Literatur und Praxis uneinheitlich definiert bzw. gehandhabt. Der Beitrag stellt die verschiedenen Leitlinien und den aktuellen wissenschaftlichen Stand vor.
Abstract
Metformin as first-line treatment in type 2 diabetes mellitus (T2 D) shows benefits in terms of reducing cardiovascular events, but the risk of a lactic acidosis as a serious adverse event especially in patients with decreased renal function is still relevant. Since the perioperative management of Metformin or its use in diagnostic procedures with contrast agents is inconsistent in literature and different in practice, the results of various guidelines are reviewed below showing the current state of evidence. Despite many guidelines, the evidence on both issues is low, as they are mainly based on consensus recommendations. The guidelines are still based on weak data and many international recommendations have clearly different statements. A fundamental problem with drugs is that expert information does specify eGFR limits for dose reduction, but not the method to be used. Depending on the formula, this can then lead to different treatment decisions. At present, it is not possible to give reliable recommendations for practice with the aim of minimising the interruption of therapy. For this reason, only a strictly conservative approach with 48-hour breaks before and after both measures can be recommended at present. For the situations mentioned in this overview, the question of the right approach has not yet been conclusively and definitely answered, therefore further studies should be carried out.
Schlüsselwörter
Metformin - Niereninsuffizienz - perioperatives Management - Kontrastmittel - Typ-2-Diabetes-mellitusKey words
metformin - renal dysfunction - perioperative management - contrast agent - type 2 diabetes mellitusPublication History
Article published online:
19 January 2021
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Tamayo T, Brinks R, Hoyer A. et al Prävalenz und Inzidenz von Diabetes mellitus in Deutschland. Dtsch Arztebl International 2016; 113: 177-182 . doi:10.3238/arztebl.2016.0177
- 2 Laurentius T, Freitag M, Eitner J. et al Glucose metabolism in older patients. Internist (Berl) 2019; 60: 133-140 . doi:10.1007/s00108-018-0542-y
- 3 Maznyczka A, Myat A, Gershlick A. Discontinuation of metformin in the setting of coronary angiography: clinical uncertainty amongst physicians reflecting a poor evidence base. EuroIntervention 2012; 7: 1103-1110 . doi:10.4244/eijv7i9a175
- 4 Wagner J, Luber V, Lock JF. et al Perioperative handling of antidiabetic drugs. Chirurg 2018; 89: 103-107 . doi:10.1007/s00104-017-0527-8
- 5 Merck Serono GmbH. Persönliche Korrespondenz: Anfragen mit Referenznummer DE-B-2020-129999 und DE-B-2020-134556. Anfragedatum 17.03.2020 und 23.04.2020
- 6 European Medicines Agency. Changes to the Product information as approved by the CHMP on 13 October 2016, pending endorsement by the European Commission. Annex III – Amendments to relevant sections of the Product Information. 2016 Im Internet (Stand 11.05.2020): www.ema.europa.eu/en/documents/referral/metformin-article-31-referral-changesproduct-information_en.pdf
- 7 Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale Versorgungs-Leitlinie Therapie des Typ-2-Diabetes. 2013 Im Internet (Stand: 11.05.2020): 1. Auflage, Version 4. www.awmf.org/uploads/tx_szleitlinien/nvl-001gl_S3_Typ-2-Diabetes-Therapie_2014-11-abgelaufen.pdf
- 8 BÄK, KBV, AWMF. Nationale Versorgungs-Leitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. 2010 zuletzt geändert September 2015. Im Internet (Stand 11.05.2020): 1. Auflage, Version 6. www.awmf.org/uploads/tx_szleitlinien/nvl-001dl_S3_Nierenerkrankungen_bei_Diabetes_Erwachsene_2015-09-abgelaufen.pdf
- 9 Joint British Diabetes Societies for inpatient care. Management of adults with diabetes undergoing surgery and elective procedures: Improving standards. Revised March 2016. Im Internet (Stand: 11.05.2020): www.diabetes.org.uk/resources-s3/2017-09/Surgical%20guidelines%202015%20-%20full%20FINAL%20amended%20Mar%202016_0.pdf
- 10 Duncan AI, Koch CG, Xu M. et al Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg 2007; 104: 42-50 . doi:10.1213/01.ane.0000242532.42656.e7
- 11 Nazer RI, Alburikan KA. Metformin is not associated with lactic acidosis in patients with diabetes undergoing coronary artery bypass graft surgery: a case control study. BMC Pharmacol Toxicol 2017; 18: 38 . doi:10.1186/s40360-017-0145-6
- 12 Barker P, Creasey PE, Dhatariya K. et al Peri-operative management of the surgical patient with diabetes 2015: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia 2015; 70: 1427-1440 . doi:10.1111/anae.13233
- 13 Cheisson G, Jacqueminet S, Cosson E. et al Perioperative management of adult diabetic patients. Preoperative period. Anaesth Crit Care Pain Med 2018; 37 (Suppl. 01) S9-S19 . doi:10.1016/j.accpm.2018.02.020
- 14 Cheisson G, Jacqueminet S, Cosson E. et al Perioperative management of adult diabetic patients. Postoperative period. Anaesth Crit Care Pain Med 2018; 37 (Suppl. 01) S27-S30 . doi:10.1016/j.accpm.2018.02.023
- 15 Whiting P, Morden A, Tomlinson LA. et al What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open 2017; 7: e012674 . doi:10.1136/bmjopen-2016-012674
- 16 The Royal College of Radiologists. Standards for intravascular contrast administration to adult patients. 2015 Im Internet (Stand 11.05.2020): 3rd Edition. www.rcr.ac.uk/sites/default/files/Intravasc_contrast_web.pdf
- 17 Owen RJ, Hiremath S, Myers A. et al Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J 2014; 65: 96-105 . doi:10.1016/j.carj.2012.11.002
- 18 European Society of Urogenital Radiology. ESUR Guidelines on Contrast Agents. 2018 Im Internet (Stand: 11.05.2020): 10th Version.
- 19 van der Molen AJ, Reimer P, Dekkers IA. et al Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018; 28: 2856-2869 . doi:10.1007/s00330-017-5247-4
- 20 Nyman U, Ahlkvist J, Aspelin P. et al Preventing contrast medium-induced acute kidney injury: Side-by-side comparison of Swedish-ESUR guidelines. Eur Radiol 2018; 28: 5384-5395 . doi:10.1007/s00330-018-5678-6
- 21 European Society of Urogenital Radiology. ESUR Guidelines on Contrast Media. 2012 Im Internet (Stand 11.05.2020): www.esur.org/guidelines/
- 22 The Royal Australian and New Zealand College of Radiologists. Iodinated Contrast Media Guideline. Version 2.3. 2018. Im Internet (Stand 11.05.2020): www.ranzcr.com/documents/573-iodinated-contrastguidelines-2016/file
- 23 American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. 2020 Im Internet (Stand 11.05.2020): www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf
- 24 Hiremath S, Kayibanda JF, Chow BJW. et al Drug discontinuation before contrast procedures and the effect on acute kidney injury and other clinical outcomes: a systematic review protocol. Syst Rev 2018; 7: 34 . doi:10.1186/s13643-018-0701-1
- 25 Goergen SK, Rumbold G, Compton G. et al Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254: 261-269 . doi:10.1148/radiol.09090690
- 26 Salpeter SR, Greyber E, Pasternak GA. et al Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010; 4 DOI: 10.1002/14651858.CD002967.pub4.